Who we are

At Inke, we are dedicated to developing and manufacturing the highest quality Active Pharmaceutical Ingredients with a focus on complex synthesis processes, particularly for use in respiratory therapies

With a rich history dating back to 1980, Inke has established itself as a leader in the fine chemical and pharmaceutical industry, known for our unwavering commitment to excellence and innovation.

Our Commitment to Excellence

We take pride in our ability to deliver high-added-value APIs that meet the stringent standards required for respiratory therapies. Our portfolio includes a range of essential substances such as Formoterol, Glycopyrronium, Indacaterol, Salmeterol, Tiotropium, Umeclidinium and Vilanterol, each meticulously developed and manufactured to the highest standards of quality and efficacy.

Our Story

2024

1980

2023

Acquisition by VC Keensight Capital

The latest in our series of strategic developments, Inke was acquired by venture capital firm Keensight Capital. This new chapter promises to leverage Keensight’s expertise in fostering high-growth potentials, focusing on further innovations and expanding our global reach. This acquisition set a new direction for our company’s future.

2022

Plant Expansion to Increase Capacity for Inhalation APIs

We embarked on a significant expansion of our manufacturing plant to increase our production capacity for inhalation APIs. This expansion was driven by growing demand in the respiratory care market and aimed at enhancing our supply chain resilience.

2020

Acquisition by Funds Advised by Permira

Continuing our trajectory of growth, Inke was acquired by funds advised by Permira. This partnership focused on bolstering our R&D capabilities and speeding up the commercialization of new products.

2019

FDA inspection (6th inspection)
Our facility underwent its 6th FDA inspection, which was successfully completed with no observations. This milestone underscores our ongoing commitment to maintaining the highest standards of quality and compliance in the pharmaceutical industry.

2017

Spanish Health Authorities GMP inspection
(4th inspection)

Our facility has successfully completed its 4th GMP inspection by the Spanish Health Authorities. This achievement reaffirms our dedication to upholding stringent Good Manufacturing Practices and ensuring the highest quality in our pharmaceutical manufacturing processes.

2016

Acquisition by Funds Advised by Apax

The acquisition by funds advised by Apax Partners was a key step in our journey, providing Inke with the capital to invest in cutting-edge technologies and expand our market presence globally.

FDA inspection (5th inspection)

2012

Korean agency (KFDA) inspection

Our facility has successfully passed the inspection conducted by the Korean Food and Drug Administration (KFDA). This accomplishment highlights our adherence to rigorous regulatory standards and our commitment to delivering high-quality pharmaceutical products to the global market.

2008

Spanish Health Authorities GMP inspection
(1st inspection)

Our facility successfully completed its first GMP inspection by the Spanish Health Authorities. This initial inspection marks a significant milestone, demonstrating our commitment to adhering to the highest standards of Good Manufacturing Practices and ensuring exceptional quality in our pharmaceutical products.

2005

Acquisition by Invent Farma

A strategic milestone, Inke was acquired by Invent Farma, which expanded our resources and enabled further growth and expansion into new markets, enhancing our capabilities in drug development and production.

2002

First FDA Inspection

Inke’s facilities passed their first U.S. Food and Drug Administration (FDA) inspection without any critical observations, a testament to our high standards of quality and compliance with stringent regulatory requirements.

2000

ISO 14001 certification

Our facility proudly achieved ISO 14001 certification for environmental management. This longstanding certification underscores our long-term commitment to sustainable practices and our dedication to minimizing environmental impact through effective management systems. Maintaining this standard over the years has been crucial to our operational integrity and environmental responsibility.

1998

Development of First Respiratory Product – Formoterol

Inke achieved a major milestone by developing its first respiratory product, which catered to a growing need in the healthcare sector for more effective respiratory medications. This development underlined our commitment to addressing critical health issues through innovation.

1986

First Micronizer Installed – Loratadine

Marking a significant technological advancement, Inke installed its first micronizer. This equipment was pivotal in enhancing the precision and efficiency of our pharmaceutical formulations, setting a new standard in our production capabilities

1980

Foundation of Inke S.A.

Inke S.A. was founded with a vision to innovate and lead in the pharmaceutical manufacturing industry, specializing initially in the production of generic active pharmaceutical ingredients.

Headquartered in Barcelona, Spain, Inke has established a strong global presence

Ensuring delivery of APIs to Europe, the US, Japan, Korea, and China, and maintaining excellence across all international markets

Canada, USA & Mexico

For detailed information on this market, please reach out to Eric Bouillet.

Japan

For detailed information on this market, please reach out to Mónica Capón

Africa

Turkey, South Africa, MENA (Egypt, Algeria, Morocco & Tunisia)

For detailed information on this market, please reach out to Maite Pascual.

India, Bangladesh & Pakistan

For detailed information on this market, please reach out to Maite Pascual.

INKE S.A.

Main Offices:

Avinguda Diagonal, 605 6D,
08028 Barcelona, Spain

Manufacturing Site:

Area Industrial del Llobregat,
Argent 1, 08755 Castellbisbal
Barcelona, Spain

LATAM

Argentina & Brazil

For detailed information on this market, please reach out to Maite Pascual.

Europe

For detailed information on this market, please reach out to Anna Homs.

Spain

For detailed information on this market, please reach out to Maite Pascual.

Asia & Oceania

China, Korea, Taiwan and Southest Asia (Vietnam, Philippines, Thailand & Malaysia), Australia & New Zealand

For detailed information on this market, please reach out to Harry Yuan.

Our Activities

  • Inke has been manufacturing the highest quality API since 1980
  • Development and manufacturing of API with complex synthesis process
  • More than 20 years’ experience in micronisation
  • Continuous international expansion since 1998
  • Strong international presence with the sale of APIs to more than 30 countries

Commitment to Quality, Innovation, and Success

Your Trusted Partner in Pharmaceutical Excellence

At Inke, we are dedicated to partnering with our clients to provide exceptional products and services that drive success. With our unwavering commitment to quality, innovation, and customer satisfaction, Inke stands as your trusted partner in pharmaceutical excellence.